Jim Mellon's Juvenescence takes a chance on tiny upstart run by former Pfizer exec
When Margaret Jackson was doing some consulting work for Juvenescence CEO Greg Bailey last year, she did not anticipate the anti-aging biotech venture would eventually …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.